18 Jun 2018 13:22
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 May 2018
Net Assets | £235m |
Net Assets per share | 626p |
Share price | 595p |
Total value of unquoted investments | £23m |
Total number of portfolio companies | 78 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Neurocrine | 5.5 |
Celgene | 4.8 |
Biogen | 4.3 |
Vertex | 4.1 |
Array | 4.0 |
Illumina | 3.9 |
Sage | 3.9 |
Morphosys | 3.7 |
Genmab | 3.6 |
Adamas | 3.4 |
----------- | |
Total | 41.2 |
Geographical Allocation | % NAV |
US & Canada | 86 |
Europe | 14 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 90 |
Unquoted | 10 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 35 |
Mid Cap =USD1-10BN | 41 |
Small Cap | 24 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 43 |
CNS | 16 |
Rare diseases | 11 |
Inflammation | 6 |
Ophthalmology | 6 |
Infectious Diseases | 3 |
Metabolic | 3 |
Medtech | 2 |
Other | 10 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
18 JUNE 2018
Int.biotech. (IBT)